Source link : https://www.newshealth.biz/health-news/fda-oks-vyvgart-hytrulo-for-cidp/
The US Food and Drug Administration (FDA) has approved the combination of efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo, argenx) for treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare and often debilitating autoimmune disorder. Efgartigimod alfa–hyaluronidase is the first neonatal Fc receptor blocker approved for the treatment of CIDP and will be available […]
Author : News Health
Publish date : 2024-06-24 21:26:50
Copyright for syndicated content belongs to the linked Source.
Categories